Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ULTI.OL
- Price
- 12.80
- Stock movement down
- -0.20 (-1.54%)
- Company name
- Ultimovacs ASA
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 44.04M
- Ent value
- -62.18M
- Price/Sales
- -
- Price/Book
- 0.23
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 22.62%
- 1 year return
- -86.80%
- 3 year return
- -75.42%
- 5 year return
- -55.46%
- 10 year return
- -
Last updated: 2025-04-15
DIVIDENDS
ULTI.OL does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.23 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.44M |
| EPS (TTM) | -43.39 |
| FCF per share (TTM) | -52.65 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -2.96M |
| Operating income (TTM) | -162.35M |
| Net income (TTM) | -149.28M |
| EPS (TTM) | -43.39 |
| EPS (1y forward) | -10.81 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 131.00M |
| Net receivables | 0.00 |
| Total current assets | 140.07M |
| Goodwill | 11.74M |
| Intangible assets | 61.48M |
| Property, plant and equipment | 2.49M |
| Total assets | 215.79M |
| Accounts payable | 4.08M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 12.33M |
| Total liabilities | 24.78M |
| Shareholder's equity | 191.01M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -181.12M |
| Capital expenditures (TTM) | 17.00K |
| Free cash flow (TTM) | -181.13M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -78.15% |
| Return on Assets | -69.18% |
| Return on Invested Capital | -78.15% |
| Cash Return on Invested Capital | -94.83% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 12.80 |
| Daily high | 13.50 |
| Daily low | 12.20 |
| Daily Volume | 4K |
| All-time high | 1620.00 |
| 1y analyst estimate | 57.50 |
| Beta | 0.99 |
| EPS (TTM) | -43.39 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 May 2025 |
Downside potential
Loading...
Downside potential data
| ULTI.OL | S&P500 | |
| Current price drop from All-time high | -99.21% | -12.89% |
| Highest price drop | -99.89% | -56.47% |
| Date of highest drop | 1 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -46.40% | -11.07% |
| Avg time to new high | 37 days | 12 days |
| Max time to new high | 882 days | 1805 days |
COMPANY DETAILS
Marketcap
44.04M
Marketcap category
Small-cap
Description
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Employees
17
Website
Investor relations
-
SEC filings
CEO
Country
Norway
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WO...
February 28, 2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WO...
February 13, 2025
Ultimovacs ASA (FRA:7UM) Q4 2024 Earnings Call Highlights: Strategic Merger and Financial Challenges
Despite significant financial losses and workforce reductions, Ultimovacs ASA's merger with Zelluna Immunotherapy aims to revolutionize cancer treatment with innovative TCRNK technology.
February 1, 2025
Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results toda...
January 31, 2025
Oslo, January 27, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, invites to a webcast presentation of its fourt...
January 27, 2025
Oslo, 9 January 2025: Reference is made to the stock exchange notices published by Ultimovacs ASA (the "Company") on (i) 17 December 2024 regarding the contemplated business combination between the Co...
January 9, 2025
Oslo, 19 December 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated business combination between the Compa...
December 19, 2024
Oslo, 19 December 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated business combination between the Compa...
December 19, 2024
Reference is made to the stock exchange announcement by Ultimovacs ASA ("Ultimovacs" or the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS...
December 17, 2024
Reference is made to the stock exchange announcement by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS (the "Business ...
December 17, 2024
Next page